MET and glioblastoma: For example, bozitinib (PLB-1001) is a highly selective ATP-competitive c-MET inhibitor with blood-brain barrier permeability allowing for its potential utility in secondary GBM, where a significant proportion of patients carry METex14 alterations which are associated with a poor prognosis (177).